Fluorouracil plus leucovorin induces submandibular salivary gland enlargement in rats

Toxicologic Pathology

Volumn 33, Issue 4, 2005, Pages 507-515

  Ewens, Andrew D ^a   Mihich, Enrico ^a   Ehrke, M Jane ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 fluorouricil; Rats; Sialoadenitis; Submandibular salivary gland; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIARRHEA; FACE EDEMA; FEMALE; HISTOPATHOLOGY; NONHUMAN; PAROTID GLAND; PRIORITY JOURNAL; RAT; SIALOADENITIS; STOMATITIS; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WEIGHT; BONE MARROW CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EDEMA; ERYTHROID CELLS; FEMALE; FLUOROURACIL; HEMATOCRIT; HEMOGLOBINS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LEUCOVORIN; LEUKOCYTES; RATS; RATS, INBRED F344; SUBMANDIBULAR GLAND;

EID: 22244442495     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230490966265     Document Type: Article

References (34)

1. Abbas, M., Amir, S., Elham, I., and Alia, M. (1986). Effect of 5-fluorouracil on the submandibular salivary gland of rats: an assessment by electron microscopy. Egyptian Dent J 32, 195-207.
2. Bruckner, H. (1988). Mount Sinai Clinical Experience with Leucovorin and 5-Fluorouracil. Plenum Press, New York.
3. Calabresi, P., and Chabner, B. (1990). Antineoplastic Agents. Pergamon Press, New York.
4. Campora, E., Esposito, M., Civalleri, D., Gogioso, L., Decian, F., Balletto, N., Falcone, A., Nobile, M., Parodi, B., Cafaggi, S., and Bignardi, G. (1987). Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. Anticancer Res 7, 829-32.
5. Cao, S. T., and Rustum, Y. (1998). Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res 58, 1695-9.
6. Celio, L., DiGregoio, J., Ruch, E., Pace, J., and Piraino, A. (1983). 5-Fluorouracil concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. J Pharm Sci 72, 597-9.
7. Cunningham, J., Bukowski, R., Budd, G. J. W., and Purvis, J. (1984). 5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. Invest New Drugs 2, 391-5.
8. Diasio, R. B., and Harris, B. E. (1989). Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215.
9. Donowitz, G., and Quesenberry, P. (1986). 5-fluorouracil effect on cultured murine stem cell progeny and peripheral leukocytes. Exp Hematol 14, 207-14.
10. Evans, R. M., Laskin, J. D., and Hakala, M. T. (1981). Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41, 3288-95.
11. Gnepp, D., and El-Mofty, S. (1996). Salivary Glands. Mosby, St. Louis.
12. Gyves, J. (1985). Pharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C. Sem Oncol 12, 29-32.
13. Haines, R., Johnson, A., and Petering, H. (1967). Symposium on immunosuppressive drugs. Variable influences of antitumor drugs and progestational agents on immune responses in rodents. Fed Proc 26, 934-43.
14. Hayashi, Y., and Watanabe, J. (1990). Salivary excretion of 5-fluorouracil (5-FU). V. Effect of 5-FU concentration in perfusate on the salivary excretion of 5-FU in perfused rat mandibular gland. Chem Pharm Bull 38, 2008-11.
15. Heidelberger, C. (1965). Fluorinated pyrimidines. Prog Nucleic Acid Res 4, 1-50.
16. Jones, R. B., Myers, C. E., Guarino, A. M., Dedrick, R. L., Hubbard, S. M., and DeVita, V. T. (1978). High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol 1, 161-6.
17. Joulia, J., Pinguet, F., Ychou, M., Duffour, J., Astre, C., and Bressolle, F. (1999). Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer 35, 296-301.
18. Kuzuya, T., Yamauchi, M., Ito, A., Hasegawa, M., Hasegawa, T., and Nabeshima, T. (1994). Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 46, 685-9.
19. Lokich, J., and Moore, C. (1984). Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101, 798.
20. MacMillan, W. E., Wolberg, W. H., and Welling, P. G. (1978). Pharmacokinetics of fluorouracil in humans. Cancer Res 38, 3479-82.
21. Madajewicz, S., Petrelli, N., Rustum, Y., Campbell, J., Herrera, L., Mittelman, A., Perry, A., and Creaven, P. (1984). Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44, 4667-69.
22. Mahteme, H., Larsson, B., Sundin, A., and Graf, W. (1998). 5-FU uptake in liver metastases after intravenous and intraperitoneal administration: an autoradiographic study in the rat. Anticancer Res 18, 943-50.
23. Marsoni, S. (1995). Fluorouracil and folinic acid in colon cancer. IMPACT Investigators. Lancet 345, 1582-3.
24. Mini, E., Trave, R., Rustum, Y. M., and Bertino, J. R. (1990). Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharm Ther 47, 1-19.
25. O'Connell, M. J. (1989). A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63, 1026-30.
26. Radley, J., Hodgson, G., Thean, L., Zangheri, O., and Levin, J. (1980). Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-fluorouracil. Exp Hematol 8, 1129-38.
27. Ramos, K. S., Chacon, E., and Acosta, D. (1996), Toxic responses of the heart and vascular systems. In Casarelt and Doull's Toxicology The Basic Science of Poisons (C. D. Klaassen, ed.). McGraw-Hill Health Professions Division, New York.
28. Regelson, W., and Parker, G. (1986). The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Inves 4, 29-42.
29. Rolston, K., and Bodey, G. (1997). Infections in Patients with Cancer. Williams and Wilkins, Baltimore.
30. Slavik, M., Wu, J., and Riley, C. (1993). Salivary excretion of anticancer drugs. Ann NY Acad Sci 694, 319-21.
31. Sonis, S., Koplovsky, A., Mitus, J., Rosenthal, D., and Brand, M. (1992). Relationship of chemotherapy-induced mucositis and myelosuppression in hamsters. Eur J Cancer Oral, Oncol 28B:43.
32. Sonis, S., Woods, P., and White, B. (1990). Oral complications of cancer therapies. Pretreatment oral assessment. NC1 Monogr 9, 29-32.
33. Speyer, J., Collins, J. M., Dedrick, R. L., Brennan, M., Buckpitt, A., Londer, H., De Vita, V. T., and Myers, C. E. (1980). Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40, 567-72.
34. Sugarbaker, P., Gianola, P., Speyer, J., Wesley, R., Barofsky, I., and Meyers, C. (1985). Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98, 414-22.